

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial

Maurizio Cutolo, Gary E. Myerson, Roy M. Fleischmann, Frédéric Lioté, Federico Díaz-González, Filip Van den Bosch, Helena Marzo-Ortega, Eugen Feist, Kamal Shah, ChiaChi Hu, Randall M. Stevens, and Airi Poder

ABSTRACT. Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular inflammatory mediator synthesis by elevating cyclic adenosine monophosphate levels. The PALACE 2 trial evaluated apremilast efficacy and safety in patients with active psoriatic arthritis (PsA) despite prior conventional disease-modifying antirheumatic drugs and/or biologic therapy.

Methods. Eligible patients were randomized (1:1:1) to placebo, apremilast 20 mg BID, or apremilast 30 mg BID. At Week 16, patients with swollen and tender joint count improvement < 20% entered early escape, with placebo patients rerandomized (1:1) to apremilast 20 mg BID or 30 mg BID while apremilast patients continued on their initial apremilast dose. At Week 24, patients remaining on placebo were rerandomized to apremilast 20 mg BID or 30 mg BID. The primary endpoint was the proportion of patients achieving > 20% improvement in American College of Rheumatology response criteria (ACR20) at Week 16.

Results. In the intent-to-treat population (N = 484), ACR20 at Week 16 was achieved by more patients receiving apremilast 20 mg BID [37.4% (p = 0.0002)] and 30 mg BID [32.1% (p = 0.0060)] versus placebo (18.9%). Clinically meaningful improvements in signs and symptoms of PsA, physical function, and psoriasis were observed with apremilast through Week 52. The most common adverse events were diarrhea, nausea, headache, and upper respiratory tract infection. Diarrhea and nausea generally occurred early and usually resolved spontaneously with continued treatment. Laboratory abnormalities were infrequent and transient.

Conclusion. Apremilast demonstrated clinical improvements in PsA for up to 52 weeks, including signs and symptoms, physical function, and psoriasis. No new safety signals were observed. ClinicalTrials.gov identifier: NCT01212757. (J Rheumatol First Release July 15 2016; doi:10.3899/jrheum.151376)

Key Indexing Terms:

APREMILAST
PHASE III CLINICAL TRIAL

PSORIASIS

PSORIASIS ARTHRITIS
PHOSPHODIESTERASE 4 INHIBITOR

From the Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Genoa, Italy; Arthritis and Rheumatology of Georgia, Atlanta, Georgia; Metroplex Clinical Research Center, Dallas, Texas, USA; AP-HP, Hôpital Lariboisière, Rheumatology Department, Université Paris Diderot, Paris, France; University of La Laguna, Hospital Universitario de Canarias, La Laguna, Spain; UZ Gent, Ghent, Belgium; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Charité – Universitätsmedizin Berlin, Department for Rheumatology and Clinical Immunology, Berlin, Germany; Celgene Corp., Summit, New Jersey, USA; Clinical Research Centre Ltd., Tartu, Estonia.

Study sponsored by Celgene Corp. Editorial support for this article funded by Celgene. The authors are fully responsible for all content and editorial decisions. M. Cutolo has received research grants and/or consulting fees from Actelion, Bristol-Myers Squibb, Mundipharma, and Sanofi-Aventis. G.E. Myerson has received research grants and/or consulting fees from AbbVie, Actelion, Amgen, Bioventus, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Pfizer, Primus, Roche (Genentech), Takeda, and UCB. These authors have received research grants and/or consulting

fees from Celgene Corp.: R.M. Fleischmann, F. Lioté, F. Díaz-González, and F. Van den Bosch. E. Feist has received research grants and/or consulting fees from Bristol-Myers Squibb, Eli Lilly, and Novartis. K. Shah and C. Hu are employees of Celgene Corp. R.M. Stevens is a former employee of Celgene Corp.

M. Cutolo, MD, University of Genoa; G.E. Myerson, MD, Arthritis and Rheumatology of Georgia; R.M. Fleischmann, MD, Metroplex Clinical Research Center; F. Lioté, MD, AP-HP, Hôpital Lariboisière, Université Paris Diderot; F. Díaz-González, MD, University of La Laguna, Hospital Universitario de Canarias; F. Van den Bosch, MD, UZ Gent; H. Marzo-Ortega, MD, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; E. Feist, MD, Charité – Universitätsmedizin Berlin; K. Shah, MD, Celgene Corp.; C. Hu, EdM, MS, Celgene Corp.; R.M. Stevens, MD, Celgene Corp.; A. Poder, MD, Clinical Research Centre Ltd.

Address correspondence to Dr. M. Cutolo, Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Viale Benedetto XV, 6 16136 Genoa, Italy. E-mail: mcutolo@unige.it

Accepted for publication May 31, 2016.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2016. All rights reserved.

Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease that affects 0.3% to 1.0% of the general population¹ and can lead to decreased physical function, impaired activities of daily living, and longterm disability^{2,3,4,5}. Because of the disease's chronicity, PsA treatment needs to be longterm, with the primary goals of maximizing health-related quality of life through control of symptoms and maintenance of patient function⁶. Current PsA therapy includes conventional synthetic disease-modifying antirheumatic drugs (csDMARD) and/or biologic agents^{7,8,9,10}. Consistent efficacy in addressing the clinical manifestations of PsA has not been found with csDMARD^{8,10,11}, which are associated with safety and tolerability concerns in some patients^{9,12,13}. While many biologic DMARD (bDMARD) offer clinical and functional improvements for patients with PsA and affect radiographic progression of arthritis-related structural damage^{14,15,16}, there are safety concerns that require monitoring^{17,18}. Moreover, loss of efficacy and tolerability may limit longterm use of bDMARD for some patients¹⁹. New effective treatment options with an improved safety profile are needed for PsA.

Apremilast, an orally administered therapy, selectively targets phosphodiesterase 4 (PDE4) to downregulate the inflammatory cascade. PDE4 is an intracellular enzyme that helps regulate the expression of a network of proinflammatory and antiinflammatory mediators through degradation of cyclic adenosine monophosphate. *In vitro*, inhibition of PDE4 with apremilast has been shown to inhibit production of Th1, Th2, and Th17 cytokines²⁰. In patients with PsA, apremilast treatment significantly decreased serum levels of proinflammatory cytokines interleukin 8 (IL-8), tumor necrosis factor (TNF)- α , and IL-6 during the first 24 weeks, and significantly decreased IL-6, IL-23, and IL-17 levels and increased antiinflammatory cytokines/biomarkers (IL-10, IL-1RA) over 40 weeks²¹.

The multinational Psoriatic Arthritis Longterm Assessment of Clinical Efficacy (PALACE) clinical development program, comprising 4 phase III randomized, placebo-controlled studies with open-label extensions, is evaluating apremilast in active PsA. PALACE 1²¹, 2, and 3²² assessed the efficacy and safety of apremilast 20 mg BID and 30 mg BID versus placebo in adult patients with active PsA despite prior treatment with csDMARD and/or biologics, including therapeutic failures, or concurrent csDMARD. These studies shared similar designs, except that PALACE 3 required ≥ 1 qualifying psoriasis lesion ≥ 2 cm. PALACE 2 included a higher proportion of European Union sites, which may have contributed to the lower proportion of patients in this study with prior bDMARD exposure. Our report describes results for PALACE 2 for up to 52 weeks of apremilast treatment.

MATERIALS AND METHODS

Study design. The phase III PALACE 2 study consisted of 3 treatment periods. In the placebo-controlled period, patients were randomized (1:1:1) to placebo, apremilast 20 mg BID, or apremilast 30 mg BID, stratified by baseline csDMARD use. The apremilast dose was titrated over the first

treatment week, with increases of 10 mg/day until the target dose was reached.

Patients whose swollen joint count (SJC) and tender joint count (TJC) had not improved by $\geq 20\%$ at Week 16 were defined as nonresponders and rerandomized (1:1) to apremilast 20 mg or 30 mg if initially randomized to placebo; if initially randomized to apremilast, treatment continued without a dose change. At Week 24, all patients who were still receiving placebo were rerandomized to apremilast 20 mg or 30 mg. Upon completing the 52-week blinded active-treatment period, patients could enter a longterm open-label phase of up to 5 years' duration. Institutional review boards of the participating medical centers approved the study protocol, and all patients provided written informed consent before any study-related procedures were conducted.

Patients. Eligible patients were aged ≥ 18 years with a documented diagnosis of PsA with duration ≥ 6 months who met the Classification Criteria for Psoriatic Arthritis (CASPAR)²³. Patients had to have ≥ 3 swollen and ≥ 3 tender joints despite prior treatment with csDMARD and/or bDMARD or concurrent treatment with csDMARD. TNF-inhibitor therapeutic failures were limited to $\leq 10\%$ of randomized patients.

Patients with prior therapeutic failure of > 3 agents for PsA (csDMARD or bDMARD) or > 1 TNF inhibitor were ineligible. Patients could not have used phototherapy within 4 weeks, bDMARD (including adalimumab, etanercept, golimumab, infliximab, certolizumab pegol, or tocilizumab) within 12 weeks, or alefacept and ustekinumab within 24 weeks of randomization. Exclusions were prior apremilast treatment, active tuberculosis (TB), history of incompletely treated TB, or significant infection within 4 weeks of screening. No purified protein derivative or QuantiFERON screening for latent TB was required. There was no requirement to hold study medication for patients who developed an infection during the study and no prohibition on vaccinations in the protocol. Patients with erythrodermic, guttate, or generalized pustular psoriasis were excluded.

Concomitant medications. Patients were not required to be taking concurrent csDMARD therapy. Patients taking concurrent csDMARD at baseline could continue stable doses of methotrexate (MTX; ≤ 25 mg/week), leflunomide (≤ 20 mg/day), sulfasalazine (≤ 2 g/day), or a combination of these agents. A single reduction in a csDMARD dose was allowed between weeks 24 and 52. Patients could continue nonsteroidal antiinflammatory drugs if they were stable for ≥ 2 weeks before screening, and oral glucocorticoids (prednisone ≤ 10 mg or equivalent) if they were stable for ≥ 1 month before screening. These were permitted as background therapy, except ≤ 24 h before each study visit: low-potency topical glucocorticoids for treatment of face, axillae, and groin psoriatic lesions, coal tar shampoo and/or salicylic acid scalp preparations for scalp lesions, and nonmedicated emollient for body lesions.

Topical therapies for psoriasis, except those permitted for background therapy, were not allowed, including topical glucocorticoids, topical retinoids or vitamin D analog preparations, tacrolimus, pimecrolimus, or anthralin; immunosuppressive systemic therapy, including cyclosporine, oral retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, azathioprine, and fumaric acid esters; and phototherapy (ultraviolet B, psoralen + ultraviolet A).

Efficacy assessments. The primary efficacy endpoint was the proportion of patients achieving an American College of Rheumatology (ACR20) response at Week 16, modified for PsA by including the first carpometacarpal joint and distal interphalangeal joint involvement of the feet to the total joint count^{24,25}. Modified ACR20 response was defined as a $\geq 20\%$ improvement from baseline in SJC and TJC, based on evaluation of 76 swollen and 78 tender joints, plus $\geq 20\%$ improvement in ≥ 3 of these outcomes: (1) patient's global assessment of disease activity [0-100 mm visual analog scale (VAS)], (2) physician's global assessment (PGA) of disease activity (VAS), (3) patient's assessment of pain (VAS), (4) Health Assessment Questionnaire-Disability Index (HAQ-DI), and (5) serum C-reactive protein (CRP) level.

The key secondary endpoint was change in HAQ-DI at Week 16. Additional secondary endpoints included proportions of patients achieving modified ACR50 and ACR70 responses, minimal clinically important differ-

ences (MCID) in HAQ-DI score (change from baseline ≥ 0.13 or ≥ 0.30) based on the literature at the time of protocol development^{26,27}, 28-joint Disease Activity Score based on CRP (DAS28-CRP) < 2.6 , Medical Outcomes Study Short Form-36 questionnaire (SF-36, version 2) physical functioning domain score, European League Against Rheumatism (EULAR) good or moderate response (good = DAS28-CRP ≤ 3.2 and improvement from baseline > 1.2 ; moderate = DAS28-CRP > 3.2 and improvement from baseline > 1.2 , or DAS28-CRP ≤ 5.1 and improvement from baseline > 0.6 and ≤ 1.2), modified Psoriatic Arthritis Response Criteria (mPsARC), 50% and 75% reduction from baseline Psoriasis Area and Severity Index score (PASI-50 and PASI-75), and changes in individual ACR components and Clinical Disease Activity Index (CDAI) score. A posthoc analysis for the more recently published MCID ≥ 0.35 was also conducted²⁸.

Safety assessments. Safety was evaluated at screening and weeks 0, 4, 16, 24, 28, 40, and 52 or at time of withdrawal based on adverse events (AE), vital signs, physical examination, and clinical laboratory measurements; a 12-lead electrocardiogram was obtained at screening and weeks 0, 16, 24, and 52. AE were classified using the Medical Dictionary for Drug Regulatory Activities classification system.

Statistical analysis. The sample size calculation was based on results from a phase II apremilast study²⁹. A sample of 165 patients/group would be needed to yield 95% power to detect a 20% difference between apremilast treatment and placebo in ACR20 response, using a 2-group chi-squared test with a 2-sided 0.025 significance level.

Efficacy during the placebo-controlled period, including weeks 16 and 24, was evaluated for the intent-to-treat population, which included all patients who were randomized and received ≥ 1 dose of study medication. Sensitivity analysis was conducted for the per-protocol population, which included the intent-to-treat population with ≥ 1 post-baseline ACR evaluation and no critical protocol violations. Protocol violations excluding patients from the per-protocol population and all data-handling rules were determined before unblinding of the 24-week database. The primary endpoint, ACR20 response at Week 16, was analyzed using the Cochran-Mantel-Haenszel test, controlling for baseline DMARD use (yes/no); missing values were handled using the nonresponder imputation rule. Pairwise comparisons of each apremilast group versus the placebo group were performed using the Hochberg procedure to maintain type 1 error at 0.05. Results were considered statistically significant if both of the apremilast versus placebo comparisons achieved $p < 0.05$, or one of the comparisons achieved $p < 0.025$.

The key secondary endpoint, change from baseline HAQ-DI score at Week 16, was analyzed using an ANCOVA model, with treatment and baseline csDMARD use (yes/no) as factors and baseline value as a covariate; missing values were handled using the last observation carried forward (LOCF) methodology. Formal pairwise comparisons were conducted conditional on the test results of the primary endpoint and followed the Hochberg procedure, as described. Other binary and continuous variables were analyzed using the same methodology as described. Percent changes from baseline were analyzed based on the ANCOVA model using the rank transformation. For Week 24 analyses, patients who entered early escape at Week 16 were considered as having missing values at Week 24; the nonresponder imputation or LOCF imputed data were then applied as appropriate.

Efficacy analyses with no comparisons to placebo, including those at Week 52, were performed using observed data as prespecified.

Safety outcomes were analyzed among the safety population, comprising all randomized patients who received ≥ 1 dose of study medication. Results are presented for the placebo-controlled period (weeks 0–24), which included data through Week 16 for patients who initially received placebo and who escaped early, and data through Week 24 for all other patients, and for the 0- to 52-week period of apremilast exposure, which included all apremilast-exposure data, regardless of when treatment started (weeks 0, 16, or 24).

RESULTS

Patients. Overall, 484 patients were randomized and received ≥ 1 dose of study medication (Appendix 1). At Week 16,

55.3% (88/159) of patients receiving placebo, 36.2% (59/163) of patients receiving apremilast 20 mg, and 39.5% (64/162) of patients receiving apremilast 30 mg had $< 20\%$ improvement in SJC and TJC and entered early escape. A total of 428 (88.4%) patients completed Week 24, including those who escaped. Overall, 361 patients completed 52 weeks: 76.7% (125/163) of patients initially randomized to apremilast 20 mg, 70.4% (114/162) of patients initially randomized to apremilast 30 mg, and 76.7% (122/159) of patients randomized to placebo at baseline, including 60 patients receiving placebo/apremilast 20 mg and 62 patients receiving placebo/apremilast 30 mg (Appendix 1).

Patient demographics and disease characteristics were balanced across treatment groups (Table 1). The patient population was primarily white (95.0%), which is similar to populations in other PsA studies^{30,31}. Similar proportions of patients in each treatment group were receiving csDMARD at baseline (69.8% to 71.1%), most commonly MTX. The mean (median; range) baseline MTX dose was similar in patients receiving placebo [14.6 mg/week (15.0; 5.0–25.0)], apremilast 20 mg [15.5 mg/week (15.0; 7.5–25.0)], and apremilast 30 mg [14.6 mg/week (15.0; 5.0–25.0)]. Similar proportions of patients in each treatment group had prior bDMARD exposure (14.2%–17.2%), and bDMARD had failed for 4.3% to 6.1%.

Primary efficacy endpoint: ACR20 response. At Week 16, a significantly greater proportion of patients receiving apremilast 20 mg (37.4%; $p = 0.0002$) and 30 mg (32.1%; $p = 0.006$) achieved an ACR20 response versus placebo (18.9%; Figure 1A). Sensitivity analysis, based on the per-protocol population, demonstrated consistent results (apremilast 20 mg: 38.4%, 61/159, $p = 0.0002$; apremilast 30 mg: 34.4%, 52/151, $p = 0.0024$; placebo: 19.5%, 30/154). In subgroup analyses, greater ACR20 response was seen at Week 16 with apremilast versus placebo, regardless of prior treatment experience. Higher absolute ACR20 response rates were observed in bDMARD-naïve patients versus bDMARD-experienced patients and bDMARD failures. In bDMARD-naïve patients, 39.3% of patients receiving apremilast 20 mg (53/135; $p = 0.0009$ vs placebo), 34.3% receiving apremilast 30 mg (46/134; $p = 0.0130$), and 20.7% receiving placebo (28/135) achieved an ACR20 response. In the small subpopulation of bDMARD-experienced patients, 28.6% receiving apremilast 20 mg BID (8/28), 21.7% receiving apremilast 30 mg (5/23), and 8.7% receiving placebo (2/23) achieved an ACR20 response. Greater ACR20 response was seen at Week 16 with apremilast versus placebo in patients with or without concomitant DMARD use. For patients receiving concurrent csDMARD treatment, ACR20 response was achieved by 41.2% (47/114) of patients receiving apremilast 20 mg ($p = 0.0007$), 36.6% (41/113) receiving apremilast 30 mg ($p = 0.0079$), and 20.4% (23/113) receiving placebo. A similar pattern, but lower response, was observed among patients not receiving concurrent csDMARD

Table 1. Baseline demographic and clinical characteristics: intent-to-treat population (N = 484). The “n” reflects the no. randomized patients who received at least 1 dose of study medication; actual no. patients available for each endpoint may vary slightly owing to missing data.

Characteristics	Placebo, n = 159	Apremilast	
		20 mg BID, n = 163	30 mg BID, n = 162
Age, yrs, mean (SD)	51.2 (11.0)	50.9 (11.8)	50.5 (11.2)
Female, n (%)	85 (53.5)	95 (58.3)	95 (58.6)
Race, n (%)			
White	152 (95.6)	151 (92.6)	157 (96.9)
Asian	3 (1.9)	9 (5.5)	1 (0.6)
Black	2 (1.3)	1 (0.6)	1 (0.6)
Other	2 (1.3) ^a	2 (1.2)	3 (1.9)
Region, n (%)			
North America	35 (22.0)	38 (23.3)	43 (26.5)
Europe	106 (66.7)	103 (63.2)	101 (62.3)
Rest of world	18 (11.3)	22 (13.5)	18 (11.1)
Weight, kg, mean (SD)	84.9 (20.3)	82.7 (21.9)	82.7 (18.9)
BMI, kg/m ² , mean (SD)	29.5 (6.5)	29.3 (6.6)	29.2 (6.2)
Duration, yrs, mean (SD)			
PsA	7.8 (8.3)	7.8 (8.6)	6.8 (7.6)
Psoriasis	17.8 (13.9)	17.9 (14.1)	18.7 (14.5)
PsA subtype, n (%)			
Asymmetrical oligoarthritis	49 (30.8)	43 (26.4)	42 (25.9)
Symmetric polyarthritis	101 (63.5)	109 (66.9)	101 (62.3)
Predominant DIP joint involvement	4 (2.5)	7 (4.3)	7 (4.3)
Predominant spondylitis	1 (0.6)	2 (1.2)	5 (3.1)
Arthritis mutilans	3 (1.9)	2 (1.2)	7 (4.3)
Missing	1 (0.6)	0 (0.0)	0 (0.0)
SJC (0–76), mean (SD)	9.2 (6.6)	10.4 (7.8)	10.3 (8.1)
TJC (0–78), mean (SD)	18.0 (13.5)	20.3 (16.6)	21.8 (16.8)
HAQ-DI (0–3), mean (SD)	1.2 (0.60)	1.1 (0.62)	1.2 (0.62)
DAS-28 (CRP), mean (SD)	4.5 (1.1)	4.6 (1.0)	4.7 (1.0)
PASI score (0–72) ^b , mean (SD)	8.6 (10.0)	7.4 (6.5)	7.8 (7.3)
Presence of enthesitis, n (%)	104 (65.4)	107 (65.6)	101 (62.3)
Presence of dactylitis, n (%)	66 (41.5)	77 (47.2)	73 (45.1)
Prior use of conventional DMARD			
only (biologic-naïve), n (%)	135 (84.9)	135 (82.8)	134 (82.7)
Prior use of biologics, n (%)	23 (14.5)	28 (17.2)	23 (14.2)
Prior biologic therapeutic failures, n (%)	8 (5.0)	10 (6.1)	7 (4.3)
Baseline DMARD use, n (%)	113 (71.1)	114 (69.9)	113 (69.8)
MTX, mean dose 14.9 mg/week	94 (59.1)	94 (57.7)	91 (56.2)
LEF, mean dose 18.1 mg/day	17 (10.7)	17 (10.4)	21 (13.0)
SSZ, mean dose 1.8 g/day	17 (10.7)	18 (11.0)	12 (7.4)
Baseline glucocorticoids, mean dose ^c :			
6.29 mg/day, n (%)	20 (12.6)	36 (22.1)	25 (15.4)

^aIncluding 1 patient with missing data. ^bExamined among patients with baseline psoriasis BSA \geq 3% and PASI score at baseline (placebo, n = 72; apremilast 20 mg BID, n = 80; apremilast 30 mg BID, n = 72). ^cAll converted to oral prednisone dose. BMI: body mass index; DAS28: 28-joint Disease Activity Score; DMARD: disease-modifying antirheumatic drug; HAQ-DI: Health Assessment Questionnaire–Disability Index; PASI: Psoriasis Area and Severity Index; PsA: psoriatic arthritis; SJC: swollen joint count; TJC: tender joint count; DIP: distal interphalangeal; MTX: methotrexate; LEF: leflunomide; SSZ: sulfasalazine.

[apremilast 20 mg: 28.6% (14/49); apremilast 30 mg: 22.4% (11/49); placebo: 15.2% (7/46)]. The small sample size of the subgroup without concurrent csDMARD did not provide sufficient power to detect treatment differences.

Subgroup analysis by PsA subtype showed similar ACR20 response rates at Week 16 in the apremilast-treated patients for asymmetrical oligoarthritis and symmetrical polyarthritis subtypes (Figure 1B). The number of individuals with

predominant distal interphalangeal joints, arthritis mutilans, and predominant spondylitis was too small to analyze separately.

At Week 24, greater improvement in ACR20 response was seen with apremilast 20 mg and 30 mg versus placebo but not in ACR50 or ACR70 responses. In patients initially randomized to apremilast and remaining on treatment up to Week 52, overall ACR20 response was sustained over 52




Figure 1. (A) ACR20 in intent-to-treat population at Week 16 and (B) ACR20 by psoriatic arthritis subtype at Week 16. * $p < 0.05$, $^{\dagger}p < 0.005$ versus placebo. ‡ Included predominant distal interphalangeal joint involvement, predominant spondylitis, and arthritis mutilans. ACR20: 20% improvement in modified American College of Rheumatology response criteria.

weeks (Figure 2A, Figure 2B). At Week 52, 52.9% of patients initially randomized to apremilast 20 mg and 52.6% initially randomized to apremilast 30 mg achieved an ACR20 response (Table 2). Patients initially randomized to placebo who were rerandomized to apremilast demonstrated consistent results (Table 2; Figure 2B).

HAQ-DI. At Week 16, mean change from baseline in HAQ-DI score was significantly greater with apremilast 20 mg (-0.17 , $p = 0.032$) and 30 mg (-0.23 , $p = 0.0042$) versus placebo (-0.07 ; Table 3). The per-protocol population sensitivity analysis was consistent with the primary analysis (apremilast 20 mg: -0.17 , $p = 0.0319$; apremilast 30 mg:

-0.23 , $p = 0.0047$; placebo: -0.07). At Week 24, mean change in HAQ-DI from baseline was significantly greater with apremilast 30 mg (-0.24 , $p = 0.0191$) versus placebo (-0.10). Improvement with apremilast 20 mg (-0.17) was not significantly different from placebo (-0.10).

Improvements in HAQ-DI scores were observed in patients initially randomized to apremilast and completing 52 weeks (Figure 2C). At Week 52, mean changes in HAQ-DI scores were -0.19 (apremilast 20 mg) and -0.33 (apremilast 30 mg; Table 2). A total of 36.8% (46/125) of patients initially randomized to apremilast 20 mg and 47.0% (55/117) initially randomized to apremilast 30 mg achieved an MCID ≥ 0.35 .






Figure 2. (A) ACR20/50/70, (B) ACR20, and (C) HAQ-DI over 52 weeks (data as observed). ACR20: 20% improvement in modified American College of Rheumatology response criteria; HAQ-DI: Health Assessment Questionnaire–Disability Index; n/m: no. responders/no. patients with sufficient data for evaluation.

Table 2. Efficacy results at Week 52 (data as observed). The “n” reflects the no. patients who completed 52 weeks; actual no. patients available for each endpoint may vary. n/m = no. responders/no. patients with sufficient data for evaluation.

Results	Placebo/20 mg BID, n = 60	Placebo/30 mg BID, n = 62	Apremilast 20 mg BID, n = 125	Apremilast 30 mg BID, n = 114
ACR20, n/m (%)	32/60 (53.3)	29/61 (47.5)	64/121 (52.9)	61/116 (52.6)
ACR50, n/m (%)	18/59 (30.5)	17/62 (27.4)	32/120 (26.7)	22/118 (18.6)
ACR70, n/m (%)	10/59 (16.9)	9/63 (14.3)	12/123 (9.8)	8/118 (6.8)
HAQ-DI (0–3), mean change (SD)	–0.21 (0.48)	–0.31 (0.60)	–0.19 (0.57)	–0.33 (0.51)
SF-36v2 PF, mean change ^a (SD)	4.1 (9.1)	6.0 (9.6)	4.1 (8.8)	5.0 (9.7)
EULAR good/moderate response, n/m (%)	42/60 (70.0)	40/62 (64.5)	85/125 (68.0)	79/117 (67.5)
mPsARC response, n/m (%)	47/60 (78.3)	44/60 (73.3)	89/123 (72.4)	85/114 (74.6)
DAS28-CRP, mean change (SD)	–1.2 (1.0)	–1.2 (1.4)	–1.1 (1.1)	–1.3 (1.0)
DAS28-CRP < 2.6, n/m (%)	15/60 (25.0)	21/62 (33.9)	35/125 (28.0)	21/118 (17.8)
CDAI (0–76), mean change (SD)	–13.7 (9.8)	–13.1 (13.1)	–12.0 (10.5)	–14.4 (11.5)
SJC (0–76), mean percent change (SD)	–78.0 (42.0)	–70.1 (53.3)	–71.8 (40.6)	–73.6 (40.9)
TJC (0–78), mean percent change (SD)	–54.8 (45.4)	–43.7 (68.8)	–46.4 (56.9)	–51.8 (40.6)
CRP, normal range: 0–0.5, mg/dl, mean change (SD)	–0.16 (1.6)	0.14 (2.0)	–0.07 (2.4)	–0.03 (1.2)
PtGA (0–100 mm VAS), mean change (SD)	–9.8 (27.8)	–13.7 (27.8)	–11.3 (28.3)	–12.4 (26.7)
PGA (0–100 mm VAS), mean change (SD)	–35.5 (20.7)	–33.4 (21.4)	–30.7 (21.7)	–33.5 (21.4)
Patient’s assessment of pain (0–100 mm VAS), mean change (SD)	–15.6 (23.8)	–16.0 (24.5)	–13.5 (27.8)	–12.9 (26.5)
PASI-50, n/m (%) ^b	11/23 (47.8)	17/30 (56.7)	29/59 (49.2)	33/56 (58.9)
PASI-75, n/m (%) ^b	3/23 (13.0)	7/30 (23.3)	16/59 (27.1)	22/56 (39.3)

^aIncrease indicates improvement. ^bExamined among patients with BSA \geq 3% at baseline who had data at Week 52 (placebo/apremilast 20 mg BID, n = 23; placebo/apremilast 30 mg BID, n = 30; apremilast 20 mg BID, n = 59; apremilast 30 mg BID, n = 56). ACR20: 20% improvement in modified American College of Rheumatology response criteria; ACR50: 50% improvement in modified ACR response criteria; ACR70: 70% improvement in modified ACR response criteria; CDAI: Clinical Disease Activity Index; CRP: C-reactive protein; DAS28: 28-joint Disease Activity Score; EULAR: European League Against Rheumatism; HAQ-DI: Health Assessment Questionnaire–Disability Index; mPsARC: modified Psoriatic Arthritis Response Criteria; PASI-50: 50% reduction from baseline Psoriasis Area and Severity Index score; PASI-75: 75% reduction from baseline PASI score; SF-36v2 PF: Medical Outcomes Study Short Form-36 questionnaire version 2 physical functioning domain; SJC: swollen joint count; TJC: tender joint count; VAS: visual analog scale; PtGA: patient’s global assessment of disease activity; PGA: physician’s global assessment of disease activity; BSA: body surface area.

Additional efficacy endpoints. Efficacy of apremilast versus placebo at Week 16 was seen across a number of endpoints (Table 3). Therapeutic effect continued through Week 24, including improvements in ACR20 response, HAQ-DI (apremilast 30 mg), SF-36v2 physical functioning domain (apremilast 30 mg), good/moderate EULAR response, mPsARC response (apremilast 20 mg), DAS28-CRP, CDAI, SJC, TJC, CRP (apremilast 30 mg), PGA, PASI-50, and PASI-75. At Week 52, improvements in efficacy measures were observed among patients initially randomized to apremilast and completing 52 weeks, and among those initially randomized to placebo and then randomized to apremilast at Week 16 or 24 (Table 2), including ACR20 response, HAQ-DI, SJC, TJC, PASI-50, and PASI-75.

Safety and tolerability. During the placebo-controlled period (weeks 0–24), the most common AE (occurring in \geq 5% of any treatment group) were diarrhea, nausea, headache, and upper respiratory tract infection. The nature, incidence, and severity of AE were comparable over 24 and 52 weeks (Table 4). AE leading to discontinuation were < 10% for patients exposed to either apremilast dose up to Week 52. During the 52-week apremilast-exposure period, 23 patients (5%) experienced a serious AE [(SAE); apremilast 20 mg: n = 11 (5%); apremilast 30 mg: n = 12 (5%)]. All individual SAE were

reported for 1 patient each, except depression, hypertension, and psoriatic arthropathy, which were reported for 1 patient in each treatment group. One patient receiving apremilast 20 mg developed an SAE of small intestine diverticulitis leading to treatment interruption, which resolved with intravenous antibiotics. The study drug was resumed after hospitalization without further episodes of intestinal diverticulitis.

Abnormalities in clinical chemistry and hematology variables were infrequent, with isolated changes meeting criteria to be markedly abnormal (Table 4). Most abnormalities were single values outside of normal ranges with no trends observed; patients continued apremilast treatment with no further changes in laboratory variables.

Diarrhea and nausea. During the placebo-controlled period, diarrhea and nausea were predominantly mild to moderate in severity. Mild/moderate and severe diarrhea incidence rates reported during this period were 5.0% and 0.0%, respectively, with placebo, and 12.6% and 0.3%, respectively, with apremilast. Mild/moderate and severe nausea incidence rates were 1.9% and 0.0%, respectively, with placebo, and 12.0% and 0.6%, respectively, with apremilast. A small number of patients taking apremilast reported using drug treatments directed toward these symptoms. Diarrhea and nausea generally occurred during the first 2 weeks of treatment,

Table 3. Secondary outcomes at Week 16 (intent-to-treat population). The “n” reflects the no. randomized patients who received ≥ 1 dose of study medication; actual no. patients available for each continuous endpoint may vary slightly owing to patients without a post-baseline value at or before Week 16.

Outcomes	Placebo, n = 159	Apremilast	
		20 mg BID, n = 163	30 mg BID, n = 162
ACR50, n/m (%) ^a	8/159 (5.0)	24/163 (14.7)**	17/162 (10.5)
ACR70, n/m (%) ^a	1/159 (0.6)	6/163 (3.7)	2/162 (1.2)
HAQ-DI (0–3), mean change (SD)	–0.07 (0.46)	–0.17 (0.43)*	–0.23 (0.49)**
SF-36v2 PF, mean change ^b (SD)	1.1 (9.1)	2.5 (7.9)	3.5 (8.5)*
EULAR good/moderate response, n/m (%) ^a	50/159 (31.4)	87/163 (53.4)***	79/162 (48.8)**
mPsARC response ^a , n/m (%)	53/159 (33.3)	78/163 (47.9)*	78/162 (48.1)*
DAS28-CRP, mean change (SD)	–0.3 (1.0)	–0.8 (1.0)***	–0.7 (1.1)**
DAS28 < 2.6, n/m (%) ^a	13/159 (8.2)	29/163 (17.8)*	19/162 (11.7)
CDAI (0–76), mean change (SD)	–3.6 (11.6)	–8.1 (10.6)**	–7.6 (11.3)**
SJC (0–76), mean percent change (SD)	–20.1 (68.7)	–37.2 (69.4)*	–42.2 (54.9)**
TJC (0–78), mean percent change (SD)	–0.7 (65.8)	–33.3 (48.3)***	–18.6 (72.4)*
CRP, normal range: 0–0.5, mg/dl, mean change (SD)	–0.10 (1.4)	–0.19 (2.1)	–0.13 (1.7)
PtGA (0–100 mm VAS), mean change (SD)	–4.3 (26.8)	–10.2 (26.4)*	–9.8 (29.0)
PGA (0–100 mm VAS), mean change (SD)	–10.1 (22.0)	–18.9 (24.8)**	–18.5 (23.8)**
Patient assessment of pain (0–100 mm VAS), mean change (SD)	–6.8 (23.3)	–13.0 (24.6)*	–12.1 (28.3)
PASI-50, n/m (%) ^{a,c}	10/74 (13.5)	27/80 (33.8)**	32/77 (41.6)**
PASI-75, n/m (%) ^{a,c}	2/74 (2.7)	15/80 (18.8)**	17/77 (22.1)**

* $p < 0.05$; ** $p \leq 0.005$, *** $p \leq 0.0001$ vs placebo, based on ANCOVA model for continuous endpoints and the Cochran-Mantel-Haenszel test for binary endpoints. ^aPatients who discontinued or did not have sufficient data were counted as nonresponders. ^bIncrease indicates improvement. ^cExamined among patients with BSA $\geq 3\%$ at baseline (placebo: n = 74; apremilast 20 mg BID: n = 80; apremilast 30 mg BID: n = 77). ACR50: 50% improvement in modified American College of Rheumatology response criteria; ACR70: 70% improvement in modified ACR response criteria; CDAI: Clinical Disease Activity Index; CRP: C-reactive protein; DAS28: 28-joint Disease Activity Score; EULAR: European League Against Rheumatism; HAQ-DI: Health Assessment Questionnaire–Disability Index; mPsARC: modified Psoriatic Arthritis Response Criteria; n/m: no. responders/no. patients with sufficient data for evaluation; PASI-50: 50% reduction from baseline Psoriasis Area and Severity Index score; PASI-75: 75% reduction from baseline Psoriasis Area and Severity Index score; SF-36v2 PF: Medical Outcomes Study Short Form-36 questionnaire version 2 physical functioning domain; SJC: swollen joint count; TJC: tender joint count; VAS: visual analog scale; PtGA: patient global assessment of disease activity; PGA: physician global assessment of disease activity; BSA: body surface area.

although there were occurrences throughout the study, and they were usually resolved within 1 month despite continued treatment and without medicinal intervention. Discontinuations due to diarrhea and nausea in the combined apremilast treatment group were < 2% each over 52 weeks.

AE of interest. No serious opportunistic infections, systemic vasculitis, major adverse cardiac events, or deaths occurred during the study. Patient-reported TB-related medical history included latent TB (n = 3), pulmonary TB (n = 1), and TB (n = 1). No reactivation of TB or cases of *de novo* TB were reported up to Week 52. One patient (a 30-year-old man), who was initially randomized to placebo and then rerandomized to apremilast 20 mg, was diagnosed with T cell lymphoma after 29 days of apremilast treatment; he was withdrawn from the study. Tissue diagnosis of lymphoma was not confirmed after repeated biopsies. During the apremilast-exposure period, a 58-year-old woman randomized to apremilast 20 mg developed basal cell carcinoma, which was reported as an SAE and led to treatment interruption for only several days.

Body weight. Weight decrease was reported as an AE in several patients during the 52-week apremilast-exposure period [apremilast 20 mg: 1 patient (0.4%); apremilast 30 mg: 3 patients (1.3%)]. Most patients maintained their weight within 5% of baseline; weight loss > 5% was observed in 39 patients (17.0%) exposed to apremilast 20 mg and 34 (14.8%) exposed to apremilast 30 mg. No patients with > 5% weight loss experienced clinical sequelae that can occur with weight loss, including dehydration, electrolyte disturbances, malnutrition, or cholelithiasis. No patients experienced weight loss > 20%.

DISCUSSION

In this phase III, placebo-controlled study, oral apremilast demonstrated clinical improvements in signs and symptoms, psoriasis, and physical function in patients with active PsA for up to 52 weeks. At the primary endpoint, modified ACR20 response at Week 16, both apremilast doses demonstrated statistically greater efficacy versus placebo, regardless

Table 4. Adverse events: placebo-controlled (Weeks 0 to 24) and apremilast-exposure (Weeks 0 to 52) periods.

Events	Placebo, n = 159	Weeks 0 to 24 ^a		Weeks 0 to 52 ^b	
		Apremilast		Apremilast	
		20 mg BID, n = 163	30 mg BID, n = 162	20 mg BID, n = 234	30 mg BID, n = 234
Overview of AE, n (%)					
≥ 1 AE	72 (45.3)	106 (65.0)	96 (59.3)	159 (67.9)	163 (69.7)
≥ 1 SAE	3 (1.9)	6 (3.7)	4 (2.5)	11 (4.7)	12 (5.1)
≥ 1 AE leading to withdrawal	3 (1.9)	5 (3.1)	12 (7.4)	12 (5.1)	19 (8.1)
Death	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
AE reported by ≥ 5% of patients in any treatment group, n (%)					
Diarrhea	8 (5.0)	18 (11.0)	24 (14.8)	26 (11.1)	32 (13.7)
Nausea	3 (1.9)	15 (9.2)	26 (16.0)	20 (8.5)	32 (13.7)
Headache	7 (4.4)	9 (5.5)	19 (11.7)	13 (5.6)	23 (9.8)
URTI	6 (3.8)	14 (8.6)	11 (6.8)	26 (11.1)	22 (9.4)
Nasopharyngitis	6 (3.8)	8 (4.9)	8 (4.9)	16 (6.8)	10 (4.3)
Hypertension	7 (4.4)	4 (2.5)	5 (3.1)	10 (4.3)	13 (5.6)
Select laboratory assessments, n/m ^c (%)					
ALT > 150 u/l	1/158 (0.6)	0/162 (0.0)	2/160 (1.3)	2/232 (0.9)	3/230 (1.3)
Creatinine, male > 156 μmol/l, female > 126 μmol/l	0/158 (0.0)	0/162 (0.0)	1/160 (0.6)	2/232 (0.9)	2/230 (0.9)
Hemoglobin decrease > 2.0 and value < 10.5 g/dl (male) or < 10.0 g/dl (female)	1/157 (0.6)	1/160 (0.6)	0/160 (0.0)	2/230 (0.9)	0/230 (0.0)
Leukocytes < 2.0 × 10 ⁹ /l	0/157 (0.0)	0/160 (0.0)	0/160 (0.0)	1/231 (0.4)	0/230 (0.0)
Neutrophils < 0.75 × 10 ⁹ /l	0/157 (0.0)	0/160 (0.0)	1/160 (0.6)	1/231 (0.4)	1/230 (0.4)
Platelets < 75 × 10 ⁹ /l	0/156 (0.0)	0/160 (0.0)	0/159 (0.0)	1/231 (0.4)	0/230 (0.0)

^aPlacebo-controlled period includes the data through Week 16 for patients initially receiving placebo who escaped, and the data through Week 24 for all other patients. ^bApremilast-exposure period includes all patients who received ≥ 1 dose of apremilast, regardless of when apremilast was initiated (week 0, 16, or 24). ^cRepresents patients with ≥ 1 occurrence of the abnormality (n)/patients with a baseline value of normal and ≥ 1 post-baseline value for criteria requiring baseline or patients with ≥ 1 post-baseline value for criteria not requiring baseline (m). Individual abnormalities were infrequent and returned to baseline values with continuation of apremilast administration or were associated with a concurrent medical condition or medication. AE: adverse event; SAE: serious AE; ALT: alanine aminotransferase; URTI: upper respiratory tract infection.

of prior treatment, although only about 15% of patients with prior bDMARD exposure were randomized.

Escape criteria had low thresholds, mandating that patients enter rescue treatment early. An analysis of patients randomized to apremilast at study onset who qualified for early escape at Week 16 showed that about 30% in each dose group achieved a modified ACR20 response at Week 24, suggesting that a subset of patients may require more time to achieve response (data not shown). Trends for improvements across multiple facets of PsA were observed through Week 52.

At Week 16, apremilast 20 mg was associated with a higher modified ACR20 response versus apremilast 30 mg. However, by Week 52, response rates were similar for both dose groups. Looking at the PALACE program as a whole, higher responses were generally observed for apremilast 30 mg than 20 mg at Weeks 16 and 24, with comparable AE rates for both doses.

Both apremilast doses were generally well tolerated. The safety profile was similar to that reported previously with apremilast^{22,28,32,33,34}, and comparable for the 24-week and 52-week periods. Diarrhea and nausea, the most common AE, were predominantly mild, usually occurred early, and generally resolved with continued use, and notably, without medicinal intervention. No clinically meaningful trends

were observed in vital signs or laboratory abnormalities; findings did not indicate a need for laboratory monitoring.

Efficacy over longer-term studies can be biased, because patients not responding to or tolerating therapy are more likely to discontinue. In this 52-week study, 7.1% of patients receiving apremilast at baseline discontinued because of lack of efficacy, and 7.4% discontinued because of AE. PALACE 2 patients were required to have prior treatment with csDMARD and/or bDMARD, and these results may not be comparable to patients who are treatment-naive. Although this study included individuals with prior bDMARD exposure, that subpopulation was small; thus, results reported here may not be generalizable to that patient population.

The PALACE 2 findings support available data demonstrating that apremilast is effective for the treatment of active PsA by improving signs and symptoms of PsA, physical function, and severity of psoriasis with up to 52 weeks of treatment. This study did not reveal any new safety signals, showing that apremilast is safe without the need for laboratory monitoring. The benefit:risk profile and oral route of administration suggest that apremilast may represent an effective, alternative treatment option for patients with active PsA.

ACKNOWLEDGMENT

The authors received editorial support in the preparation of this report from Jennifer Schwinn, RPh, and Kristin Carlin, RPh, MBA, of Peloton Advantage LLC and funded by Celgene Corp.

REFERENCES

1. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. *Ann Rheum Dis* 2005;64 Suppl 2:ii14-7.
2. Strand V, Sharp V, Koenig AS, Park G, Shi Y, Wang B, et al. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. *Ann Rheum Dis* 2012;71:1143-50.
3. Singh JA, Strand V. Spondyloarthritis is associated with poor function and physical health-related quality of life. *J Rheumatol* 2009;36:1012-20.
4. Zhu TY, Tam LS, Leung YY, Kwok LW, Wong KC, Yu T, et al. Socioeconomic burden of psoriatic arthritis in Hong Kong: direct and indirect costs and the influence of disease pattern. *J Rheumatol* 2010;37:1214-20.
5. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. *J Rheumatol* 2001;28:1842-6.
6. Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. *Ann Rheum Dis* 2014;73:6-16.
7. Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. *Arthritis Rheum* 1984;27:376-81.
8. Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. *Rheumatology* 2012;51:1368-77.
9. Fraser AD, van Kuijk AW, Westhovens R, Karim Z, Wakefield R, Gerards AH, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. *Ann Rheum Dis* 2005;64:859-64.
10. Salvarani C, Macchioni P, Olivieri I, Marchesoni A, Cutolo M, Ferraccioli G, et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. *J Rheumatol* 2001;28:2274-82.
11. Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg AS, Rodevand E, et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. *Ann Rheum Dis* 2014;73:132-7.
12. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. *J Am Acad Dermatol* 2008;58:826-50.
13. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. *J Am Acad Dermatol* 2009;61:451-85.
14. Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, Fitzgerald O, Winthrop K, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. *Ann Rheum Dis* 2012;71:319-26.
15. Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, Li S, Wang Y, et al. Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. *Arthritis Care Res* 2015;67:1739-49.
16. van der Heijde D, Landewe RB, Mease PJ, McInnes IB, Conaghan PG, Pricop L, et al. Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis. *Arthritis Rheumatol* 2016 Mar 25 (E-pub ahead of print).
17. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. *Ann Rheum Dis* 2012;71:4-12.
18. Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. *Ann Rheum Dis* 2014;73:529-35.
19. Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. *Br J Dermatol* 2011;164:1091-6.
20. Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. *Cell Signal* 2014;26:2016-29.
21. Schafer PH, Chen P, Fang L, Wang A, Chopra R. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1). *J Immunol Res* 2015;2015:906349.
22. Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). *Ann Rheum Dis* 2016;75:1065-73.
23. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. *Arthritis Rheum* 2006;54:2665-73.
24. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. *Arthritis Rheum* 1995;38:727-35.
25. El Miedany Y. Recent developments in management of psoriatic arthritis. *Curr Rheumatol Rev* 2005;1:9-19.
26. Kwok T, Pope JE. Minimally important difference for patient-reported outcomes in psoriatic arthritis: Health Assessment Questionnaire and pain, fatigue, and global visual analog scales. *J Rheumatol* 2010;37:1024-8.
27. Mease PJ, Ganguly R, Wanke L, Yu E, Singh A. How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines [abstract SAT0015]. *Ann Rheum Dis* 2004;63 Suppl 1:391.
28. Mease PJ, Woolley JM, Bitman B, Wang BC, Globe DR, Singh A. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. *J Rheumatol* 2011;38:2461-5.
29. Schett G, Wollenhaupt J, Papp K, Joos R, DeVlam KL, Rodrigues JF, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. *Arthritis Rheum* 2012;64:3156-67.
30. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. *Arthritis Rheum* 2004;50:2264-72.

31. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. *Arthritis Rheum* 2005;52:3279-89.
32. Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. *Lancet* 2012;380:738-46.
33. Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al. Treatment of psoriatic arthritis in a phase 3 randomized, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. *Ann Rheum Dis* 2014;73:1020-6.
34. Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. *J Rheumatol* 2015;42:479-88.

APPENDIX 1. Patient disposition through Week 52. *Excludes 4 patients who were randomized in error and did not receive any dose of study medication. †Includes withdrawal by patient, loss to followup, protocol violation, noncompliance, and other.

